Abstract
Antiepileptic drugs (AEDs) cover a broad spectrum of pathological conditions ranging from seizures following congenital or acquired brain disorders to behavioural and psychiatric disorders and recently neuropathic pain. The need for novel antiepileptics raises from the expanding field of indications as well as from the fact, that special seizure types are refractory to common AEDs. In addition, many of the conventional antiepileptic drugs exhibit an unfavourable side-effect profile. Since there is growing evidence, that NMDA receptor activation might play a crucial role in epilepsy, NMDA receptor antagonists have become compounds of interest in preventing and treating seizures. This review focuses on NMDA receptor antagonistic compounds, which are already in use for the treatment of epileptic seizures (i. e. MgSO4, felbamate) and compounds in clinical trials (i. e. remacemide, ADCI). Further interest is put on NMDA antagonists in preclinical and biological testing (memantine, dizocilpine, conantokins, Co101244 / PD174494, ifenprodil, arcaine, L-701,324, eliprodil, CGP40116, LY235959, LY233053, MRZ2 / 576, LU73068, 4-Cl-KYN). Some of the latter compounds are predominantely of academic interest (i. e. 4-Cl-KYN), others (i. e. dizocilpine, LY235959, LY233053) might be of therapeutical value when combined with conventional AEDs. In order to reduce adverse effects in antiepileptic medication using NMDA antagonists, special interest will be focused on subtype selective compounds. In this respect, Co 101244, a novel potent and selective NR1 / 2B NMDA receptor antagonist might be a lead for therapeutically promising compounds.
Keywords: antiepilptic drugs, nmda receptor, antiepileptic valproic acid vpa, magentic resonance imaging mri, adci, memantineconantokins, ifenprodil, eliprodil, glutamate site, cgp
Current Medicinal Chemistry
Title: The NMDA Receptor Complex: A Promising Target for Novel Antiepileptic Strategies
Volume: 8 Issue: 11
Author(s): B. K. Kohl and G. Dannhardt
Affiliation:
Keywords: antiepilptic drugs, nmda receptor, antiepileptic valproic acid vpa, magentic resonance imaging mri, adci, memantineconantokins, ifenprodil, eliprodil, glutamate site, cgp
Abstract: Antiepileptic drugs (AEDs) cover a broad spectrum of pathological conditions ranging from seizures following congenital or acquired brain disorders to behavioural and psychiatric disorders and recently neuropathic pain. The need for novel antiepileptics raises from the expanding field of indications as well as from the fact, that special seizure types are refractory to common AEDs. In addition, many of the conventional antiepileptic drugs exhibit an unfavourable side-effect profile. Since there is growing evidence, that NMDA receptor activation might play a crucial role in epilepsy, NMDA receptor antagonists have become compounds of interest in preventing and treating seizures. This review focuses on NMDA receptor antagonistic compounds, which are already in use for the treatment of epileptic seizures (i. e. MgSO4, felbamate) and compounds in clinical trials (i. e. remacemide, ADCI). Further interest is put on NMDA antagonists in preclinical and biological testing (memantine, dizocilpine, conantokins, Co101244 / PD174494, ifenprodil, arcaine, L-701,324, eliprodil, CGP40116, LY235959, LY233053, MRZ2 / 576, LU73068, 4-Cl-KYN). Some of the latter compounds are predominantely of academic interest (i. e. 4-Cl-KYN), others (i. e. dizocilpine, LY235959, LY233053) might be of therapeutical value when combined with conventional AEDs. In order to reduce adverse effects in antiepileptic medication using NMDA antagonists, special interest will be focused on subtype selective compounds. In this respect, Co 101244, a novel potent and selective NR1 / 2B NMDA receptor antagonist might be a lead for therapeutically promising compounds.
Export Options
About this article
Cite this article as:
Kohl K. B. and Dannhardt G., The NMDA Receptor Complex: A Promising Target for Novel Antiepileptic Strategies, Current Medicinal Chemistry 2001; 8 (11) . https://dx.doi.org/10.2174/0929867013372328
DOI https://dx.doi.org/10.2174/0929867013372328 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potassium Channel Blockers and Openers as CNS Neurologic Therapeutic Agents
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacological Characterisation and Modulation of Neuroplasticity in Humans
Current Neuropharmacology Lower Frequency of co-Morbid Medical Disorders Related to Poor Impulse Control in Parkinson’s than Alzheimer’s Disease
Current Aging Science Random Walks on Biomedical Networks
Current Proteomics Role of the GABAA Receptor in Anxiety: Evidence from animal models, molecular and clinical psychopharmacology, and brain imaging studies
Current Neuropharmacology Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Pharmacology and Drug Discovery for T-Type Calcium Channels
CNS & Neurological Disorders - Drug Targets Quality of Life of Children with Cerebral Palsy: A Cross-Sectional KIDSCREEN study in the Southern part of the Netherlands
CNS & Neurological Disorders - Drug Targets Kv1.5-Kvβ Interactions: Molecular Determinants and Pharmacological Consequences
Mini-Reviews in Medicinal Chemistry GPRASP/ARMCX Protein Family: Potential Involvement in Health and Diseases Revealed by their Novel Interacting Partners
Current Topics in Medicinal Chemistry Triplication of <i>Synaptojanin 1</i> in Alzheimer’s Disease Pathology in Down Syndrome
Current Alzheimer Research Oral L-Carnitine: Metabolite Formation and Hemodialysis
Current Drug Metabolism Free Radicals in Living Systems: In Vivo Detection of Bioradicals with EPR Spectroscopy
Current Organic Chemistry Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering Editorial (Thematic Issue: Current Status and Progress of Radiopharmaceuticals for Molecular Imaging and Targeted Therapy)
Current Medicinal Chemistry Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner
Current Alzheimer Research Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery Cardiac Monitoring in Patients with Syncope: Making that Elusive Diagnosis
Current Cardiology Reviews TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets